WO2000067724A2 - Systeme de retention gastrique pour temps de sejour prolonge dans l'estomac ou dans le tractus gastro-intestinal - Google Patents
Systeme de retention gastrique pour temps de sejour prolonge dans l'estomac ou dans le tractus gastro-intestinal Download PDFInfo
- Publication number
- WO2000067724A2 WO2000067724A2 PCT/EP2000/003824 EP0003824W WO0067724A2 WO 2000067724 A2 WO2000067724 A2 WO 2000067724A2 EP 0003824 W EP0003824 W EP 0003824W WO 0067724 A2 WO0067724 A2 WO 0067724A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chambers
- gastroretentive system
- wall
- stomach
- chamber
- Prior art date
Links
- 210000002784 stomach Anatomy 0.000 title claims abstract description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 11
- 230000014759 maintenance of location Effects 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 claims abstract description 16
- 238000005192 partition Methods 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims description 17
- 230000002496 gastric effect Effects 0.000 claims description 11
- 239000011241 protective layer Substances 0.000 claims description 11
- 229920000247 superabsorbent polymer Polymers 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 6
- 230000002035 prolonged effect Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 abstract description 10
- 210000004051 gastric juice Anatomy 0.000 description 11
- 239000002775 capsule Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
Definitions
- the active ingredient is within the gastroretentive system, is dissolved by the gastric juice and released in a controlled manner through the walls of the system, which in this respect have a membrane function.
- the particles After ingestion, the particles swell in the stomach for a longer period of time, allowing gastric juice to penetrate into the particles. Active substance is released and extracted from the particles, so that active substance is released to the stomach as a solution, which is less harmful than in solid form.
- chambers 2a, 2b, 2c etc. contain different active substances or active substance concentrations.
- the front wall 6, the outer wall 4 and the intermediate walls 3a, 3b, 3c etc. are glued, welded or sewn together at the edge.
- Another adjacent chamber 2b is initially inaccessible to the gastric juice, since access to the interior is closed by the protective layer 5a which is initially impenetrable to gastric juice. Their substance is such that it dissolves very slowly in the stomach over time and gradually releases the access of the gastric fluid to the further chamber 2b.
- this second chamber 2b as in the first chamber 2a, or as in conventional gastroretentive systems, there is also a gas generator or a super absorber. This therefore only swells after a long time when the gas generation in the first chamber has been exhausted or the chamber has become empty.
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
La présente invention concerne un système de rétention gastrique pour temps de séjour prolongé. Des principes actifs sont libérés dans l'estomac ou dans le tractus gastro-intestinal. Le système selon l'invention comprend une enveloppe au moins partiellement semi-perméable, un agent générateur de gaz ou un polymère superabsorbant. La présente invention se caractérise en ce que l'unité de dosage (1) consiste en une poche contenant au moins deux chambres (2a, 2b, 2c, etc.) et dont la paroi avant (6) est l'enveloppe. Chaque chambre (2) est respectivement reliée à la chambre adjacente par une paroi intermédiaire commune (3a, 3b, 3c, etc.).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1999120837 DE19920837A1 (de) | 1999-05-06 | 1999-05-06 | Gastroretentives System für verlängerte Verweilzeit im Magen bzw. im Gastrointestinaltrakt |
| DE19920837.9 | 1999-05-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2000067724A2 true WO2000067724A2 (fr) | 2000-11-16 |
| WO2000067724A3 WO2000067724A3 (fr) | 2001-02-22 |
Family
ID=7907156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2000/003824 WO2000067724A2 (fr) | 1999-05-06 | 2000-04-27 | Systeme de retention gastrique pour temps de sejour prolonge dans l'estomac ou dans le tractus gastro-intestinal |
Country Status (2)
| Country | Link |
|---|---|
| DE (1) | DE19920837A1 (fr) |
| WO (1) | WO2000067724A2 (fr) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309996A (en) * | 1980-04-28 | 1982-01-12 | Alza Corporation | System with microporous releasing diffusor |
| IL87710A (en) * | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
| US5198229A (en) * | 1991-06-05 | 1993-03-30 | Alza Corporation | Self-retaining gastrointestinal delivery device |
| PL193282B1 (pl) * | 1997-01-14 | 2007-01-31 | Lohmann Therapie Syst Lts | System terapeutyczny do kontrolowanego uwalniania substancji czynnych w przewodzie żołądkowo-jelitowym |
| DE19822278A1 (de) * | 1998-05-18 | 1999-12-02 | Lohmann Therapie Syst Lts | Vorrichtung zur kontrollierten Freisetzung von Wirkstoff im Gastrointestinaltrakt mit verzögerter Pyloruspassage |
-
1999
- 1999-05-06 DE DE1999120837 patent/DE19920837A1/de not_active Withdrawn
-
2000
- 2000-04-27 WO PCT/EP2000/003824 patent/WO2000067724A2/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| DE19920837A1 (de) | 2000-11-16 |
| WO2000067724A3 (fr) | 2001-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69011878T2 (de) | Von Hydrogel angetriebene Verabreichungsvorrichtung. | |
| DE3725824C2 (de) | Orales therapeutisches System mit systemischer Wirkung | |
| DE19800523C2 (de) | Expandierbares gastroretentives Therapie-System mit kontrollierter Wirkstofffreisetzung im Gastrointestinaltrakt | |
| DE3715224C2 (de) | Dosierungsform zur stoßweisen Freisetzung eines Arzneimittels | |
| DE60123384T2 (de) | Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert | |
| DE69331806T2 (de) | Multipartikel-arzneistoffabgabesystem mit stossweiser freisetzung | |
| DE69427664T2 (de) | PH-induzierte durch Osmose zerplatzende Abgabevorrichtungen | |
| EP0339506B1 (fr) | Système osmotique oral avec adhésion améliorée de la membrane au noyau | |
| EP0307904A1 (fr) | Formes à liberation prolongée enrobées | |
| DE19747261A1 (de) | Osmotisches Arzneimittelfreisetzungssystem | |
| EP2155172A2 (fr) | Système de rétention gastrique renfermant un corps d'alginate | |
| WO2000025742A1 (fr) | Systeme therapeutique gonflant de retention stomacale a temps de sejour prolonge dans l'estomac | |
| DD266027A5 (de) | Arzneimittelhaltige fasern mit geregelter freisetzung | |
| EP0408496A2 (fr) | Dispositif solide pour substances pharmaceutiques | |
| EP1017392B1 (fr) | Formulation medicamenteuse a liberation controlee du principe actif | |
| DE69131129T2 (de) | Abgabevorrichtung | |
| DE60214154T2 (de) | Pharmazeutisches freigabekonstrukt zur magenretention | |
| WO2000067724A2 (fr) | Systeme de retention gastrique pour temps de sejour prolonge dans l'estomac ou dans le tractus gastro-intestinal | |
| DE19906290A1 (de) | Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs | |
| EP0765158A1 (fr) | Excipient destine a la liberation controlee de principes actifs dans le tractus gastro-intestinal avec passage retarde dans le pylore | |
| ES2975960T3 (es) | Formas de dosificación osmóticas que comprenden deutetrabenazina y métodos de uso de las mismas | |
| DE69116575T2 (de) | Verabreichungssystem mit mitteln zur kontrolle des internen druckes | |
| DE10120092B4 (de) | Magensaftresistente Vorrichtung zur Freisetzung von mukoadhäsiven Wirkstoffträgern und Verfahren zur Herstellung der magensaftresistenten Vorrichtung | |
| EP1075253B1 (fr) | Preparation orale ou mucosique contenant un principe actif, a liberation regulable du principe actif et son utilisation | |
| DE102004031014A1 (de) | Vorrichtung zur gezielten Freistzung von Stoffen in einem Hohlraum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP KR US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP KR US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |